Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin

Evangelia Vlachou, Ronac Mamtani, Noah M. Hahn, Burles Johnson III, Jean Hoffman-Censits, Vivek Nimgaonkar

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Enfortumab vedotin (EV) is an antibody–drug conjugate approved alone and in combination with pembrolizumab for advanced urothelial cancer (UC). EV-related-cutaneous-events (EVCEs) are common and rarely life-threatening. Black patients are frequently under-represented in oncology trials, and dermatologic conditions may vary with race. Methods: Therefore, this retrospective analysis investigated differences in EVCE frequency between Black and White patients in an urban cohort (Johns Hopkins [JH]) and a US-based, nationwide electronic health record (EHR)-derived deidentified database (Flatiron Health [FH]) with sub-group analysis of those who had received prior pembrolizumab. Results: The study included 12 Black patients in the JH Cohort (17.1%) and 24 Black patients in the FH Cohort (7.6%). In both cohorts, the frequency of EVCEs among Black patients was higher compared to White patients (JH: 66.7% vs. 33.3%; FH: 25.0% vs. 15.8%), though not statistically significant. In the larger FH Cohort EVCEs were significantly more common among Black compared to White patients treated with prior pembrolizumab (Odds Ratio [OR]: 4.76 [95%CI: 1.42, 15.95]) and recent pembrolizumab (within 90 days of EV initiation) (OR 9.00 [95%CI: 1.94, 41.66]). Conclusion: This hypothesis-generating retrospective study, comprising the largest population of EV-treated Black patients reported to date, emphasizes the importance of attentiveness to EVCEs among Black patients, particularly with receipt of pembrolizumab.

Original languageEnglish (US)
Article number102090
JournalClinical Genitourinary Cancer
Volume22
Issue number3
DOIs
StatePublished - Jun 2024

Keywords

  • Advanced urothelial cancer
  • Antibody drug conjugate
  • Black patients
  • Bladder cancer
  • Cutaneous adverse events

ASJC Scopus subject areas

  • Urology
  • Oncology

Fingerprint

Dive into the research topics of 'Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin'. Together they form a unique fingerprint.

Cite this